

Details of IBD research survey

À : Catherine Le Berre, LOY Laura ICH

Dear Doctors Catherine Le Berre and Laura Loy,

Please see below the details regarding the IBD Research survey. In essence, PMI sponsored the research through a contract to Linkt Health to coordinate the research:

Title: Patients' perspectives on smoking and inflammatory bowel disease: an online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA)

Objective: To understand patient perceptions of how smoking has impacted their Inflammatory bowel disease. Our first objective was to assess patients' perceptions about the impact of smoking on their disease, and next to assess differences of these perceptions between CD and UC patients, with the aim to understand how different smoker profiles perceived the impact of smoking on their IBD.

Languages: The survey was made available in English, French, German, Spanish, Portuguese, Italian, Greek, Finnish, and Slovenian.

Dates: The online survey was open from 4th November 2019 to 11th March 2020 on the EFCCA website.

Collection of Data: National associations were encouraged to promote the survey online by providing their members with an online link. The questionnaire was submitted through EFCCA to IBD patients who were current smokers or had a history of smoking. Patients were not pre-screened and were eligible for inclusion if they were aged over 18 years and had a confirmed diagnosis of IBD, including CD or UC. Patients gave their consent and were not paid for participating. Data were collected anonymously and participation was entirely voluntary. Patients were informed that the survey shall not in any circumstance, construed as suggesting cigarettes and/or nicotine-containing products as treatment methods.

Agency coordinating research: Linkt Health Limited, Hong Kong. Company number 2730909

Funding & Disclosures: The research was solely sponsored by Philip Morris Products SA and coordinated by Linkt Health Ltd. The questionnaire was developed by Philip Morris Products SA in cooperation with EFCCA and reviewed prior to use by health informaticians - CLB and LL also participated in the design of the questionnaire. The sponsor had no role in data analysis or preparation of the manuscript. None of the authors received personal fees from Philip Morris International.

Thank you

Kind regards

Sati Matharu
BScPharm, MBA
Managing Director
Linkt Health Limited.

Mob: +852 5119 5076 (Hong Kong)
Email: linkthealth@gmail.com
Registered in Hong Kong. Company number 2730909
House 12, Bayview Terrace, 107 Castle Peak Road,
Tuen Mun, New Territories, Hong Kong.